UCB acquisition (κ=1.0), validated as superior to EI across six drug-discovery targets, will outperform EI in Bayesian optimisation of proton-exchange-membrane electrolyser operating strategies when the objective landscape exhibits high uncertainty in partial-load efficiency, because the same high-uncertainty-region exploration advantage that yields higher-pKd compounds also discovers non-obvious low-degradation operating points inaccessible to exploitation-biased acquisition.
Adversarial Debate Score
72% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- Differentiable hybrid force fields support scalable autonomous electrolyte discovery
Autonomous electrolyte discovery demands a computational engine that satisfies a critical trilemma: it must be fast enough for high-throughput screening, accurate enough for quantitative property pred...
- Active rejection enables reliable generalization of universal machine-learning interatomic potentials
Universal machine learning interatomic potentials (uMLIPs) bridge quantum-mechanical accuracy and large-scale molecular dynamics, but the cost of high-accuracy calculations such as r²SCAN limits train...
- Trustworthy Protein-Ligand Binding Affinity Prediction via Reliability-Aware Multi-Engine Fusion
Accurate protein-ligand binding affinity prediction is central to computational drug discovery, yet modern docking engines frequently disagree without indicating which prediction to trust. Consensus s...
- Budget-Sensitive Discovery Scoring: A Formally Verified Framework for Evaluating AI-Guided Scientific Selection
Scientific discovery increasingly relies on AI systems to select candidates for expensive experimental validation, yet no principled, budget-aware evaluation framework exists for comparing selection s...
- Unified Mapping of Multi-Site Electrocatalytic Activity Using a Single Descriptor
We present a precise and general method to map the activity of electrocatalysts across multiple sites. Starting from a mean-field statistical mechanics model, we introduce an effective adsorption free...
Computational Result
An LLM's reading of the literature — not computational verification.
UCB shows promise but context-dependent performance limits certainty.
Method: literature_meta · Result: inconclusive · Confidence: 60%
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
In Bayesian optimisation of PEM electrolyser operating strategies (current density, temperature, membrane humidification, partial-load duty cycle) against a joint objective of efficiency and degradation rate, an Upper Confidence Bound acquisition function with fixed exploration coefficient κ=1.0 will achieve a lower cumulative regret and a lower best-found degradation-adjusted-efficiency loss than Expected Improvement, when evaluated over ≥30 independent optimisation runs of ≥150 iterations each on a validated electrolyser degradation surrogate/simulator, with the UCB advantage statistically significant at p<0.05 (paired Wilcoxon signed-rank test) and effect size ≥0.3 (Cohen's d on final simplex regret), specifically in the regime where surrogate posterior predictive standard deviation in the partial-load region (<20% rated current density) exceeds 15% of the objective's dynamic range.
- No statistically significant difference (p≥0.05) between UCB and EI cumulative regret across ≥30 runs, or EI significantly outperforms UCB (reversed sign, p<0.05).
- Effect size Cohen's d <0.2 even if p<0.05 (statistically detectable but practically negligible).
- UCB's advantage disappears or reverses when uncertainty calibration is verified good (PICP within 5%) — i.e., advantage was an artifact of surrogate misspecification rather than genuine exploration value.
- UCB's discovered "low-degradation operating points" are not physically realisable or violate electrolyser safety/operating constraints (e.g., membrane dry-out, hotspot formation) more often than EI's, negating practical value even if regret is lower.
- The claimed high-uncertainty partial-load region does not in fact contain the eventual global optimum in ≥50% of test cases (i.e., exploration was not rewarded).
Spine & Adversarial Read
- highThe analogy to drug discovery is superficial pattern-matching — pKd landscapes and electrochemical degradation surfaces have no established shared structural properties (smoothness, multimodality, noise structure) that would mechanistically justify transferring an acquisition-function preference across domains.The protocol requires an explicit landscape-characterization step (uncertainty heteroscedasticity quantification, calibration checks) rather than assuming transfer, but the EVP does not yet include a formal similarity metric between the drug-discovery landscapes and electrolyser landscapes; this remains a gap unless a landscape-similarity analysis (e.g., comparing GP length-scale distributions, multimodality indices) is added as a prerequisite step.
- mediumWhy choose GP-based UCB/EI and this particular surrogate/simulator combination rather than other established BO benchmarking standards (e.g., BBOB/COCO test functions, or ensemble-NN acquisition, or existing published electrolyser digital twins)? The methodology choice needs explicit justification against alternatives.Justification given: GP surrogates are the standard substrate for both UCB/EI theory and the cited drug-discovery study, enabling direct comparability; the dual surrogate+simulator design is included specifically to guard against surrogate-only artifacts. However, the EVP does not justify why alternative published electrolyser digital twins (if they exist) weren't prioritized over building a custom Butler-Volmer model — this should be resolved by a literature search for existing validated electrolyser BO benchmarks before building a new simulator from scratch, to avoid duplicated effort.
- mediumWith only 30 repetitions and a 4-6 dimensional space, statistical power may be insufficient to detect the claimed effect size reliably, especially given BO's inherent run-to-run variance, risking both false negatives and false positives depending on variance structure.Interim power analysis is built into Checkpoint 3, and effect-size (not just p-value) reporting is required; a formal a priori power calculation (target power=0.8 for d=0.3 requires ~90 paired samples for Wilcoxon, exceeding the planned 30) is not yet included and should be added — current n=30 is likely underpowered for the stated d≥0.3 threshold and the sample size should be revised upward or the detectable effect size threshold relaxed accordingly.
Experimental Protocol
Minimum viable test: a controlled head-to-head Bayesian optimisation benchmark on (a) a physics-informed PEM electrolyser degradation surrogate built from published degradation/efficiency datasets, and (b) at least one open-source electrochemical simulator (e.g., a Butler-Volmer + membrane-degradation ODE model) as a secondary independent objective function, to guard against surrogate-specific artifacts. Both UCB (κ=1.0) and EI are run with identical GP surrogates (Matern-5/2 kernel, same initialization, same random seeds for initial design), 30 repetitions each, 150 iterations each, on a 4-6 dimensional operating-strategy search space. Primary outcome: simple regret and cumulative regret trajectories; secondary outcome: best degradation-adjusted efficiency found and its physical plausibility.
- Published PEM electrolyser degradation datasets (e.g., NREL H2New consortium degradation data, EU FCH-JU durability test datasets, or peer-reviewed papers reporting voltage-degradation-vs-operating-condition tables) to fit/ground the surrogate — target ≥500 labeled operating-condition/degradation-rate pairs.
- An open-source or reproducible electrochemical PEM model (e.g., a 1D/0D Butler-Volmer + Nafion degradation kinetic model implementable in Python/COMSOL) as a synthetic ground-truth oracle for BO benchmarking.
- BoTorch/Ax or GPyTorch implementations of GP surrogates with UCB and EI acquisition functions (open source, version-pinned).
- The original six drug-discovery-target benchmark suite (if available, e.g., a DOI/repo reference) to first replicate the UCB>EI claim in its original domain as a positive control before cross-domain transfer testing.
- Held-out validation set of real (or high-fidelity simulated) electrolyser operating points not used in surrogate fitting, for out-of-sample regret evaluation.
- Paired Wilcoxon p<0.05 favoring UCB on final cumulative regret across both oracles (surrogate and simulator), with Cohen's d≥0.3.
- UCB identifies operating points with ≥10% lower predicted degradation rate at equal or better efficiency than EI's best point, in ≥60% of the 30 runs.
- Calibration check confirms PICP within 5% of nominal, ruling out miscalibration as confound.
- Effect replicates (same sign, comparable magnitude) on both the surrogate and the independent physics simulator, and in the sensitivity sweep for κ∈{0.5,1.0,2.0} the qualitative UCB>EI ranking is preserved for at least 2 of 3 κ values.
- p≥0.05 or Cohen's d<0.2 on primary regret comparison.
- Effect present on surrogate but absent/reversed on independent physics simulator (indicates surrogate-artifact, not real transfer).
- UCB's "improved" points are physically infeasible or violate safety constraints more than EI's in >20% of runs.
- Calibration check shows PICP deviates >15% from nominal, invalidating uncertainty-driven mechanism claim.
- Positive control (drug-discovery replication) fails to reproduce original UCB>EI result — indicates pipeline error, aborts before cross-domain claim is tested.
ROI Projection
Implementation Sketch
# Pseudocode load_drug_discovery_benchmark() -> replicate UCB_kappa1 vs EI -> assert p<0.05 (positive control) surrogate = fit_GP(electrolyser_dataset, kernel=Matern52) validate_calibration(surrogate) -> PICP check simulator = ElectrochemicalODEModel(ButlerVolmer, NafionDegradationKinetics) for oracle in [surrogate, simulator]: for acq_fn in [UCB(kappa=1.0), EI()]: for rep in range(30): X_init = sobol_sample(n=10, seed=rep) gp = fit_GP(X_init, oracle(X_init)) for t in range(150): x_next = optimize_acquisition(acq_fn, gp) y_next = oracle(x_next) gp = update_GP(gp, x_next, y_next) log(regret(t), best_found(t)) statistical_test(UCB_results, EI_results, method="paired_wilcoxon") compute_effect_size(cohens_d) plausibility_check(best_points, constraint_set) sensitivity_sweep(kappa=[0.5,1.0,2.0], acq=[EI, EI_tuned])
- Checkpoint 1 (Day 5): If positive-control replication of drug-discovery UCB>EI result fails, abort and debug pipeline before proceeding.
- Checkpoint 2 (Day 15): If surrogate calibration check fails (PICP deviation >15%), halt and re-fit/re-collect data before running full BO comparison.
- Checkpoint 3 (Day 25): After first 10 of 30 reps per condition, run interim significance/power analysis; if effect size trending <0.1, consider early stopping (with correction for interim analysis) rather than completing full budget.
- Checkpoint 4 (Day 35): If surrogate and simulator results qualitatively disagree in sign, pause and investigate before drawing cross-domain conclusions.
NAMED_EXPERTS: []
CLOSEST_EXISTING_WORK: []
NOVELTY_NARROWING_REQUIRED: false
SPINE_STATEMENT: This hypothesis tests whether a fixed-κ UCB acquisition function produces statistically and practically lower regret than Expected Improvement when Bayesian-optimising PEM electrolyser operating strategies under high partial-load uncertainty.